Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2019 1
2020 2
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland.
Adamczyk M, Bartosińska J, Raczkiewicz D, Adamska K, Adamski Z, Czubek M, Kręcisz B, Kłujszo E, Lesiak A, Narbutt J, Noweta M, Owczarczyk-Saczonek A, Owczarek W, Reich A, Samotij D, Siekierko A, Szczęch J, Walecka I, Ciechanowicz P, Woźniacka A, Liszewska A, Krasowska D. Adamczyk M, et al. Among authors: klujszo e. J Clin Med. 2023 Feb 20;12(4):1675. doi: 10.3390/jcm12041675. J Clin Med. 2023. PMID: 36836209 Free PMC article.
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.
Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CEM, Barker JN, Smith CH; PsoProtect study group. Mahil SK, et al. J Allergy Clin Immunol. 2021 Jan;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007. Epub 2020 Oct 16. J Allergy Clin Immunol. 2021. PMID: 33075408 Free PMC article. Clinical Trial.
A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis.
Feldman SR, Narbutt J, Girolomoni G, Brzezicki J, Reznichenko N, Zegadlo-Mylik MA, Pulka G, Dmowska-Stecewicz M, Kłujszo E, Rekalov D, Rajzer L, Lee J, Lee M, Rho YH. Feldman SR, et al. Among authors: klujszo e. J Am Acad Dermatol. 2024 Apr 27:S0190-9622(24)00663-7. doi: 10.1016/j.jaad.2024.04.045. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38685404